Organovo Holdings, Inc. (ONVO): Price and Financial Metrics
ONVO Price/Volume Stats
| Current price | $1.71 | 52-week high | $3.72 |
| Prev. close | $1.68 | 52-week low | $1.37 |
| Day low | $1.63 | Volume | 18,200 |
| Day high | $1.73 | Avg. volume | 79,508 |
| 50-day MA | $1.94 | Dividend yield | N/A |
| 200-day MA | $1.92 | Market Cap | 14.90M |
ONVO Stock Price Chart Interactive Chart >
ONVO Stock Summary
- ORGANOVO HOLDINGS INC's market capitalization of $15,511,970 is ahead of only 6.67% of US-listed equities.
- ONVO's price/sales ratio is 9.08; that's higher than the P/S ratio of 88.29% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.11 for ORGANOVO HOLDINGS INC; that's greater than it is for merely 9.25% of US stocks.
- If you're looking for stocks that are quantitatively similar to ORGANOVO HOLDINGS INC, a group of peers worth examining would be WISH, HLGN, RAMP, SLGC, and ASAN.
- Visit ONVO's SEC page to see the company's official filings. To visit the company's web site, go to www.organovo.com.
ONVO Valuation Summary
- ONVO's price/earnings ratio is -1.3; this is 105.39% lower than that of the median Healthcare stock.
- Over the past 137 months, ONVO's price/earnings ratio has gone up 74.4.
Below are key valuation metrics over time for ONVO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ONVO | 2023-05-23 | 9.2 | 0.7 | -1.3 | 0.2 |
| ONVO | 2023-05-22 | 9.3 | 0.7 | -1.4 | 0.2 |
| ONVO | 2023-05-19 | 9.2 | 0.7 | -1.3 | 0.2 |
| ONVO | 2023-05-18 | 9.2 | 0.7 | -1.3 | 0.2 |
| ONVO | 2023-05-17 | 9.0 | 0.7 | -1.3 | 0.3 |
| ONVO | 2023-05-16 | 9.0 | 0.7 | -1.3 | 0.3 |
ONVO Growth Metrics
- Its 3 year net cashflow from operations growth rate is now at 58.51%.
- The 5 year revenue growth rate now stands at -48.09%.
- The 3 year price growth rate now stands at -81.41%.
The table below shows ONVO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 1.708 | -9.216 | -11.711 |
| 2022-09-30 | 1.577 | -9.528 | -11.947 |
| 2022-06-30 | 1.5 | -9.454 | -12.131 |
| 2022-03-31 | 1.5 | -8.453 | -11.448 |
| 2021-12-31 | 0 | -9.026 | -12.133 |
| 2021-09-30 | 0 | -7.161 | -11.144 |
ONVO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ONVO has a Quality Grade of D, ranking ahead of 17.68% of graded US stocks.
- ONVO's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
- SYRS, DRNA, and CPHI are the stocks whose asset turnover ratios are most correlated with ONVO.
The table below shows ONVO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.000 | NA | -9.390 |
| 2021-03-31 | 0.000 | NA | -11.494 |
| 2020-12-31 | 0.000 | NA | -19.890 |
| 2020-09-30 | 0.011 | 0.956 | -5936.667 |
| 2020-06-30 | 0.050 | 0.819 | -9.301 |
| 2020-03-31 | 0.062 | 0.851 | -4.771 |
Organovo Holdings, Inc. (ONVO) Company Bio
Organovo Holdings, Inc. focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company was founded in 2007 and is based in San Diego, California.
Latest ONVO News From Around the Web
Below are the latest news stories about ORGANOVO HOLDINGS INC that investors may wish to consider to help them evaluate ONVO as an investment opportunity.
Organovo Announces FXR ProgramLead Molecule Poised for Phase 2 in IBDSAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of human disease, today announced a clinical program for FXR 314, an FXR agonist that has completed initial clinical trials. FXR314 is a drug with safety and tolerability after da |
Will Organovo Holdings (NASDAQ:ONVO) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug CandidatesSAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announced that it has successfully advanced the use of its first inflammatory bowel disease (IBD) model and has achieved the next milestone, target validation. The company announced in May 2022 that it had achieved a successful Crohn’s disease model |
Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceSAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Executive Chairman, will participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12 - 14, 2022. Organovo plans to advance drugs discovered in its cutting-edge human 3D disease models in inflammatory bowel dis |
Organovo Announces Postponement of Annual Meeting of StockholdersSAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key aspects of human disease (the “Company”), today announced that its 2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”) that was scheduled to be held at 9:00AM (Pacific Time) on Wednesday, September 7, 2022 has been postponed to October 12, 2022 at 9:00AM (Pacific Time), a date determined |
ONVO Price Returns
| 1-mo | -10.94% |
| 3-mo | -6.56% |
| 6-mo | 0.59% |
| 1-year | -24.34% |
| 3-year | -86.43% |
| 5-year | -93.80% |
| YTD | 21.28% |
| 2022 | -61.16% |
| 2021 | -70.49% |
| 2020 | 72.90% |
| 2019 | -62.95% |
| 2018 | -28.36% |
Continue Researching ONVO
Here are a few links from around the web to help you further your research on Organovo Holdings Inc's stock as an investment opportunity:Organovo Holdings Inc (ONVO) Stock Price | Nasdaq
Organovo Holdings Inc (ONVO) Stock Quote, History and News - Yahoo Finance
Organovo Holdings Inc (ONVO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...